We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Algorithm Predicts Onset of COVID-19 Symptoms from Data Collected by Wearable Smart Ring

By HospiMedica International staff writers
Posted on 01 Sep 2020
Researchers are developing an algorithm to predict the onset of COVID-19 symptoms based on data collected by a wearable smartring that could also be applied to data from other wearable devices.

The UCSF Osher Center for Integrative Medicine (San Francisco, CA, USA) has been awarded USD 5.1 million by the Medical Technology Enterprise Consortium in partnership with the Department of Defense to expand a study called TemPredict. More...
The research study aims to observe associations between dermal body temperature, heart rate and related metrics, and onset of symptoms such as fever, cough, and fatigue, which can characterize COVID-19. The purpose of this study is to collect information from a wearable sensor that may allow researchers to develop an algorithm that can predict onset of symptoms such as fever, cough, and fatigue, which can characterize COVID-19.

The study uses an Oura Ring which is a wearable device that measures heart rate, inter-beat interval and changes in dermal temperature and is associated with a smartphone app. The researchers are testing whether physiological data collected by the Oura Ring, combined with responses to daily symptom surveys, can predict illness symptoms. The study aims to build an algorithm to identify patterns of, onset of, progression of, and recovery from, COVID-19.

The TemPredict study includes two groups: front-line healthcare workers and the general population. First, TemPredict has provided Oura Rings to more than 3,400 frontline responders, including doctors, nurses, paramedics, and others, who are in daily contact with patients who may be afflicted with COVID-19. Second, the study is open to all Oura Ring users. Through daily symptom surveys, study participants directly contribute their own observations, paired to their Oura data, to the research team. Researchers will use this information as they attempt to identify patterns that could predict onset, progression, and recovery in future cases of COVID-19. If this approach is successful, it could open the door for research into tracking and managing other illnesses and conditions.

TemPredict has gained momentum with over 65,000 participants and ongoing funding awards. In the past several months, TemPredict received funding from #startsmall and more recently, an USD 800,000 contract from the Department of Defense, to collect dried blood samples for COVID-19 antibody testing. Oura seeded the project in March by providing startup funds and 1,400 rings for healthcare workers. The TemPredict study has received the latest award of USD 5.1 million from the Department of Defense to complete antibody testing for 10,000 participants and provide additional support for algorithm development and testing in real-world settings. The pilot testing will allow participants who opt in to receive directives to get tested for COVID-19 based on algorithms using their smartring data. This part of the study will allow the researchers to iteratively test and improve the algorithm and evaluate how it works in the real world.

Related Links:
UCSF Osher Center for Integrative Medicine


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.